(P03-059-23) A Milk Protein Hydrolysate Decreases Inflammation on a Model of mBSA-Induced Arthritis Mice

Objectives: Osteoarthritis affects over 500 million people worldwide. Due to the global aging of the population, this incidence is constantly increasing. In order to relieve pain, people need to take Non-Steroidal Anti-Inflammatory drug (NSAI), however NSAI have known for their side effect. Thus, a natural solution, without side effects, to relieve inflammatory and pain in case of joint issue would be very interesting.

In this way, we evaluated the efficiency of a milk protein hydrolysate in an in vitro model of inflammation and in an arthritis model of mice.

Methods: In vitro experiment have been performed to evaluate casein hydrolysate on cytokine production (TNFα, IL1β, IL10) by Peripheral Blood Mononuclear Cells (PBMC) stimulated by LPS. Five doses of the casein hydrolysate have been tested and compared to a drug positive control, Dexamethasone.

After which an in vivo experiment has been performed to validate in vitro data. Casein hydrolysate has been evaluated in a model of rheumatoid arthritis induced by methylated bovine serum albumin (mBSA) in C57BL/6J mice, inducing the formation of an oedema in knee joints. For 29 days, mice received orally drinking water or casein hydrolysate at different concentration: 10, 50 and 250 mg/kg.

Results: The lowest dose of casein hydrolysate inhibit production of TNFα, IL1β, and IL10. Its effect is similar to the anti-inflammatory effect of Dexamethasone.

In vivo study has shown that after oedema formation due to the mBSA, mice receiving the casein hydrolysate at 50 mg/kg and 250 mg/kg have a significant reduction of the oedema compared to the mBSA group treated with the vehicle.

Conclusions: These in vitro and in vivo experiments demonstrated that casein hydrolysate have anti-inflammatory properties allowing to decrease by more than 60% the size of the knee oedema in mice suffering from arthritis compared to the vehicle mice. These results are promising and would make it possible to have a natural product to replace, at least in part, the taking of chronic anti-inflammatory drugs. The next step is to validate these results with a clinical study.

Funding Sources: INGREDIA S.A.